Physician profile
Etai Goldenberg
NPI 1669663605
$94,502.69
in general payments reported to CMS, 2019-2025
40 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,640 · 2020: $4,880 · 2021: $5,525 · 2022: $15K · 2023: $36K · 2024: $15K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $7,694 · Food and Beverage: $5,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $36,700.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,422.00 |
| Travel and Lodging | $7,694.26 |
| Food and Beverage | $5,795.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $51,426.34 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Endo Pharmaceuticals INC. | $24,920.81 | 2019-2024 | Xiaflex, Aveed, Edex |
| Endo USA, INC. | $9,005.81 | 2024-2025 | Xiaflex, Aveed, Edex |
| Boston Scientific Corporation | $4,669.19 | 2019-2025 | Ams 700 Cxr Rte Kit, Ams 700, Ams 800 Artificial Urinary Sphincter |
| Janssen Biotech, INC. | $410.85 | 2020-2025 | Rybrevant, Carvykti, Erleada |
| Calyxo, INC. | $407.24 | 2024-2025 | Cvac Aspiration System |
| Neotract INC. | $403.50 | 2019-2020 | |
| Urogen Pharma, INC. | $342.81 | 2024-2025 | |
| Accord Healthcare, INC. | $333.99 | 2023-2024 | |
| Teleflex LLC | $328.67 | 2021-2022 | |
| Astellas Pharma US INC | $264.88 | 2019-2023 | Myrbetriq |
| Tolmar, INC. | $208.96 | 2023-2025 | Jatenzo, Eligard |
| Procept Biorobotics Corporation | $164.89 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Tolmar Pharmaceuticals, INC. | $147.18 | 2021 | |
| Allergan, INC. | $137.06 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Etai Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.